State running out of drug to treat mucormycosis
The Hindu
Many families, hospitals finding it difficult to source them
The supply of the anti-fungal drugs Liposomal Amphotericin B or Amphotericin B, which are vital for treating mucormycosis, is drying up in Tamil Nadu with many patients’ families and hospitals finding it difficult to source them. Mucormycosis, a serious fungal infection now predominantly affecting people post-COVID-19 with uncontrolled diabetes, has been on the rise in several parts of the country. With cases gradually increasing in Tamil Nadu as well, the demand for the drug has shot up. An ENT specialist from a leading private hospital in Chennai said that Liposomal Amphotericin B or, in its absence, Amphotericin B was the first line of drug for mucormycosis and there were no effective alternatives. “Though Tamil Nadu is not yet seeing as many cases compared to other States, the drug shortage is already being felt,” he said.More Related News

The draft policy for “Responsible Digital Use Among Students”, released on Monday by the Department of Health and Family Welfare, has recommended that parents set structured routines with clear screen-time rules and prioritise privacy, safety, and open conversation with children on digital well-being.












